// App-Quantinova.ai

: Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

Researchers

Presenter

  • Pier Luigi Zinzani

Principal Investigators

  • Sam Yuen

  • Max S. Topp

  • Chiara Rusconi

  • Isabelle Fleury

  • Christopher K Arthur

  • Barbara Pro

  • Giuseppe Gritti

  • Michael Crump

  • Katell Le Du

  • Divya Samineni

  • Arijit Sinha

  • Elizabeth A Punnoose

  • Edith Szafer-Glusman

  • Nathalie Danesi

  • Adam Petrich

  • Martin Kornacker

  • Kathryn Humphrey

  • Mehrdad Mobasher

  • Wolfgang Hiddemann

Medical Centers

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Sarah Cannon Research Institute/Tennessee Oncology, Brentwood, TN

  • Calvary Mater Newcastle, Waratah, NSW, Australia

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Division of Hematology, Niguarda Ca Granda Hospital, Milan, Italy

  • Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, Canada

  • Department of Endocrinology, Royal North Shore Hospital, St Leonards, Australia

  • Northwestern University, Chicago, IL

  • Ospedale Papa Giovanni XXIII, Hematology and BMT Unit, Bergamo, Italy

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Clinique Victor Hugo, Le Mans, France

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • AbbVie, Inc., North Chicago, IL

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Genentech, Inc., South San Francisico, CA

  • Laboratory for Leukemia Diagnostics,Department of Medicine III, University Hospital, LMU Munich,Munich,Deutschland

Locations

  • Italy

  • United States

  • Australia

  • Germany

  • Canada

  • France

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02187861

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved